Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

• Status: Withdrawn
• Trial end date: 2021-05-30
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and efficacy of Ticagrelor versus Clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting stents.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing First Hospital, Nanjing Medical University
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• Patients who agreed to the experimental plan which was permitted by IRB;

• Patients planned to take dual antiplatelet therapy for 12 months.

Exclusion Criteria:

• Severe hepatic dysfunction defined as serum transaminase > 3 times normal limit;

• Renal dysfunction defined as eGFR < 30ml/min/1.73m^2;

• Co-morbidity with an estimated life expectancy of < 50 % at 12 months;

• Scheduled surgery in the next 12 months, which resulted protocol changes;

• Known allergy against study drug or device;

• Use of glycoprotein IIb/IIIa inhibitor during the perioperative period;

• Anticoagulation treatment including warfarin.